Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet.

Kimura T, Nakamura K, Miyoshi T, Yoshida M, Akazawa K, Saito Y, Akagi S, Ohno Y, Kondo M, Miura D, Wada J, Ito H.

Int Heart J. 2019 May 30;60(3):728-735. doi: 10.1536/ihj.18-392. Epub 2019 May 17.

2.

The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.

Lee HC, Shiou YL, Jhuo SJ, Chang CY, Liu PL, Jhuang WJ, Dai ZK, Chen WY, Chen YF, Lee AS.

Cardiovasc Diabetol. 2019 Apr 1;18(1):45. doi: 10.1186/s12933-019-0849-6.

3.
4.

Benidipine inhibits expression of ET-1 and TGF-beta1 in Dahl salt-sensitive hypertensive rats.

Kobayashi N, Nakano S, Mori Y, Kobayashi T, Tsubokou Y, Matsuoka H.

Hypertens Res. 2001 May;24(3):241-50.

5.

Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice.

Obata A, Kubota N, Kubota T, Iwamoto M, Sato H, Sakurai Y, Takamoto I, Katsuyama H, Suzuki Y, Fukazawa M, Ikeda S, Iwayama K, Tokuyama K, Ueki K, Kadowaki T.

Endocrinology. 2016 Mar;157(3):1029-42. doi: 10.1210/en.2015-1588. Epub 2015 Dec 29.

PMID:
26713783
6.

Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway.

Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Noda A, Izawa H, Nagata K, Yokota M.

Clin Exp Pharmacol Physiol. 2006 Dec;33(12):1164-71.

PMID:
17184496
7.

Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy.

Takasu T, Takakura S.

Life Sci. 2019 Aug 1;230:19-27. doi: 10.1016/j.lfs.2019.05.051. Epub 2019 May 21.

PMID:
31125563
8.

Early changes in excitation-contraction coupling: transition from compensated hypertrophy to failure in Dahl salt-sensitive rat myocytes.

Nagata K, Liao R, Eberli FR, Satoh N, Chevalier B, Apstein CS, Suter TM.

Cardiovasc Res. 1998 Feb;37(2):467-77.

PMID:
9614501
9.

Dietary salt restriction improves cardiac and adipose tissue pathology independently of obesity in a rat model of metabolic syndrome.

Hattori T, Murase T, Takatsu M, Nagasawa K, Matsuura N, Watanabe S, Murohara T, Nagata K.

J Am Heart Assoc. 2014 Dec 2;3(6):e001312. doi: 10.1161/JAHA.114.001312.

10.

Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension.

Shimoyama M, Hayashi D, Zou Y, Takimoto E, Mizukami M, Monzen K, Kudoh S, Hiroi Y, Yazaki Y, Nagai R, Komuro I.

Circulation. 2000 Oct 17;102(16):1996-2004.

PMID:
11034951
11.

Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats.

Louhelainen M, Vahtola E, Kaheinen P, Leskinen H, Merasto S, Kytö V, Finckenberg P, Colucci WS, Levijoki J, Pollesello P, Haikala H, Mervaala EM.

Br J Pharmacol. 2007 Apr;150(7):851-61. Epub 2007 Feb 26.

13.

Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.

Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S.

Cardiovasc Diabetol. 2016 Nov 11;15(1):157.

14.

Effects of imidapril on endothelin-1 and ACE gene expression in failing hearts of salt-sensitive hypertensive rats.

Kobayashi N, Hara K, Higashi T, Matsuoka H.

Am J Hypertens. 2000 Oct;13(10):1088-96.

PMID:
11041163
15.

AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats.

Nagata K, Somura F, Obata K, Odashima M, Izawa H, Ichihara S, Nagasaka T, Iwase M, Yamada Y, Nakashima N, Yokota M.

Hypertension. 2002 Aug;40(2):168-74.

PMID:
12154108
16.

Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.

Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, Takeda M, Yata T, Kawai M, Fukuzawa T, Kobayashi T, Sato T, Kawabe Y, Ikeda S.

J Pharmacol Exp Ther. 2012 Jun;341(3):692-701. doi: 10.1124/jpet.112.191593. Epub 2012 Mar 12.

PMID:
22410641
17.

Cardiac Hypertrophy and Brain Natriuretic Peptide Levels in an Ovariectomized Rat Model Fed a High-Fat Diet.

Goncalves GK, Caldeira de Oliveira TH, de Oliveira Belo N.

Med Sci Monit Basic Res. 2017 Dec 18;23:380-391.

18.

A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.

Ikeda S, Takano Y, Cynshi O, Tanaka R, Christ AD, Boerlin V, Beyer U, Beck A, Ciorciaro C, Meyer M, Kadowaki T.

Diabetes Obes Metab. 2015 Oct;17(10):984-93. doi: 10.1111/dom.12538. Epub 2015 Aug 20.

PMID:
26179482
19.

Teneligliptin Prevents Cardiomyocyte Hypertrophy, Fibrosis, and Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats.

Yamamoto M, Ishizu T, Seo Y, Suto Y, Sai S, Xu D, Murakoshi N, Kimura T, Kawakami Y, Aonuma K.

J Card Fail. 2018 Jan;24(1):53-60. doi: 10.1016/j.cardfail.2017.09.001. Epub 2017 Sep 6.

PMID:
28888840
20.

Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats.

Biala A, Finckenberg P, Korpi A, Loytainen M, Martonen E, Levijoki J, Mervaala E.

J Physiol Pharmacol. 2011 Jun;62(3):275-85.

Supplemental Content

Support Center